LabPMM ® Receives New York State Approval for the NPM1 MRD Assay - Informing Therapy and Accelerating Targeted Trials

SAN DIEGO--(BUSINESS WIRE)--Invivoscribe is happy to announce that its wholly owned subsidiary, the Laboratory for Personalized Molecular Medicine ® (LabPMM) has received approval from New York State (NYS) for the NPM1 MRD Assay. This approval comes just two months after gaining NYS approval for our FLT3 ITD MRD Assay. Together these tests represent a critical tool for patients with acute myeloid leukemia (AML), clinicians and pharmaceutical companies. This new approval underscores Invivoscribe's ongoing commitment to providing the most accurate, standardized measurable residual disease (MRD) testing solutions worldwide.
The NPM1 MRD Assay is a pivotal development in the fight against AML, offering an ultra-sensitive DNA sequencing method to accurately measure trace levels of residual leukemia cells in patients with the NPM1 mutation variants. NPM1 mutations are considered an ideal target for MRD assessment because they are present in ~30% of adult AML cases, 1 stable over time, 2 and, if present in blood at allele fractions ≥0.01%, are associated with increased relapse and worse overall survival. 3 Recent studies show emerging evidence that pre-transplant MRD testing for NPM1 and FLT3 -ITD identifies AML patients in remission who are most likely to relapse or experience poor survival. 3,4,5
With this approval, LabPMM is helping to transform the landscape of AML research, treatment and drug development. By using MRD as a surrogate endpoint in clinical trials, instead of relying solely on overall survival (OS), pharmaceutical companies can accelerate their drug development timelines. This is particularly valuable in acute disease, where time is of the essence, and earlier intervention can dramatically improve patient outcomes.
'We are proud to receive New York State approval for our NPM1 MRD Assay by NGS, marking our second assay approved by New York State this year,' said Jordan Thornes, V.P., Global Clinical Laboratory Operations at LabPMM. 'This milestone reflects our continued dedication to advancing precision diagnostics in cancer care. With this latest approval, we're further empowering clinicians with sensitive, reliable tools to detect residual disease and guide treatment decisions with confidence.'
LabPMM's NPM1 and FLT3 ITD MRD Assays are standardized next generation sequencing (NGS) tests that complement the LeukoStrat ® CDx FLT3 Mutation Assay, which is used to guide treatment selection for patients with AML. These services are offered in the U.S., European Union, and across Asia to ensure patients around the world have access to high-quality, standardized testing and to support the development of cutting-edge cancer treatments. LabPMM remains committed to advancing precision medicine and improving outcomes for patients worldwide. For more information about the NPM1 MRD Assay and LabPMM's full test menu, please visit https://invivoscribe.com/clinical-lab-services/ or contact us at inquiry@invivoscribe.com and follow us on LinkedIn.
About Invivoscribe
Invivoscribe ® is a global, vertically integrated biotechnology company dedicated to Improving Lives with Precision Diagnostics ®. For thirty years, Invivoscribe has improved the quality of healthcare worldwide by providing high quality standardized reagents, tests, and bioinformatics tools to advance the field of precision medicine. Invivoscribe has a successful track record of partnerships with pharmaceutical companies interested in clinical trial testing via our global lab network located in the U.S., Germany, Japan and China, and in developing and commercializing companion diagnostics, with our rigorous expertise in both regulatory and laboratory services. Providing distributable kits, as well as clinical trial services through its globally located clinical lab subsidiaries (LabPMM ®), Invivoscribe is an ideal partner from diagnostic development, through clinical trials, regulatory submissions, and commercialization.

Try Our AI Features

Explore what Daily8 AI can do for you:

Learn with AIFact CheckingText to SpeechAI Summary

Related Articles

Yahoo

16 hours ago

• Yahoo

LegalBison Establishes Southeast Asia Presence with New Malaysian Office

New Kuala Lumpur office strengthens LegalBison's regional reach and enhances regulatory support across Asia. Kuala Lumpur, Malaysia--(Newsfile Corp. - June 20, 2025) - LegalBison, a global regulatory advisory firm specializing in the FinTech and crypto sectors, has officially opened its new office in Kuala Lumpur, marking the company's first physical expansion into Asia and reinforcing its long-term growth strategy in emerging financial markets. LegalBison To view an enhanced version of this graphic, please visit: This milestone follows the success of LegalBison's European headquarters in Tallinn, Estonia, and represents a strategic effort to better serve clients throughout Southeast Asia-including Malaysia, Singapore, Indonesia, Thailand, and beyond. "Availability for international clients has always been one of LegalBison's key strengths," said Sabir Alijev, Chief Product Officer at LegalBison. "With our new presence in Malaysia, we now have a bird's-eye view of the local regulatory landscape and are ready to deliver timely, regionally tailored solutions." Kuala Lumpur was selected for its robust regulatory institutions, economic stability, and position as a rising hub for digital finance in Asia. Establishing operations in Malaysia allows LegalBison to deepen relationships with local partners and clients while offering more agile support in licensing, AML/KYC compliance, cross-border banking, and corporate structuring. LegalBison's move reflects the growing demand for localized compliance expertise in Asia's fast-evolving financial landscape. The Malaysian team will collaborate closely with LegalBison's Estonia office to provide seamless advisory services across time zones, ensuring clients benefit from both global perspective and local insight. By anchoring its Asia-Pacific strategy in Kuala Lumpur, LegalBison positions itself as a trusted partner to startups, growth-stage firms, and enterprises navigating complex cross-border regulatory environments. LegalBison is now actively onboarding clients across Southeast Asia and is open to strategic partnerships throughout the region and globally. For media inquiries or more information, please visit or contact pr@ About LegalBison Founded in 2020, LegalBison is a regulatory and legal advisory firm headquartered in Tallinn, Estonia. The firm supports companies in the FinTech, crypto, and high-compliance sectors with services including licensing, compliance, banking solutions, and international corporate structuring. LegalBison provides tailored, cross-border support to help businesses navigate complex regulatory environments worldwide. Media Contact LegalBison PR Teampr@ 20 4577 To view the source version of this press release, please visit

Medscape

18 hours ago

• Medscape

Fast Five Quiz: Cancer Diagnostics and Precision Medicine

Over the past decade, precision medicine has transformed cancer diagnostics and treatment by tailoring therapy to a patient's tumor biology based on molecular alterations rather than histologic subtypes or origins. Precision oncology often relies on molecular profiling through next-generation sequencing (NGS) to identify genomic events that can guide management. Techniques like targeted panels, whole-exome sequencing (WES), and whole-genome sequencing (WGS) provide different analysis levels, chosen based on tumor type, tissue, and therapy relevance. How much do you know about cancer diagnostics and precision medicine? Test your knowledge with this quick quiz. WGS is an NGS method that analyzes the entire DNA sequence of an organism, including both coding and noncoding regions. WGS offers broad genomic coverage, detecting structural variants, intergenic mutations, and copy number changes often missed by targeted methods. Clinically, it has been useful in identifying ERBB2 ( HER2 ) amplifications in breast cancer or complex epidermal growth factor receptor ( EGFR ) alterations in lung cancer that might not be captured by smaller panels, helping guide targeted therapy. However, its lower sequencing depth (30-60×) typically limits the detection of low-frequency variants in heterogeneous tumors, such as a subclonal TP53 mutation affecting a small subset of cells and potentially impacting treatment response, which WGS may miss due to its lower depth. WES focuses only on the protein-coding regions, offering greater depth than WGS but limited breadth; however, it misses important regulatory and noncoding mutations. For example, TERT promoter mutations in glioblastoma are clinically relevant but lie outside the exome and would be missed by WES. Targeted panels are NGS tests that focus on specific disease-related genes and, until recently, were the predominant method used for comprehensive genomic profiling in clinical settings. They offer high depth for detecting low-frequency, actionable mutations but have limited coverage and might miss rare alterations outside the selected genes. Sanger sequencing is a method that reads DNA by generating fragments of varying lengths using chain-terminating nucleotides. It is accurate for small regions but has low throughput and cannot detect low-frequency mutations, making it unsuitable for large-scale cancer genomics. Unlike WGS, which surveys the entire genome, Sanger covers only targeted regions, so it does not offer broad genomic coverage and is therefore not the correct answer. Learn more about molecular profiling in oncology diagnostics. TS panels analyze specific genes relevant to oncology, and by focusing on a smaller subset of the genome (a few dozen to a few hundred genes), these panels require fewer sequencing data, resulting in faster turnaround times and simplified data interpretation compared with WGS or WES. This targeted approach enhances sensitivity for detecting clinically actionable somatic mutations, especially in small or heterogeneous tumor samples. For example, targeted NGS panels in non-small cell lung cancer (NSCLC) can rapidly detect EGFR mutations, ALK rearrangements, and other actionable alterations, allowing oncologists to initiate targeted therapies based on the mutation profile promptly. TS also demands less data storage and computational processing compared with WGS or WES, resulting in faster turnaround times and lower costs. These attributes make TS especially well-suited for clinical settings where accuracy, speed, and cost-effectiveness are paramount Learn more about clinical practice guidelines in the use of precision medicine in oncology. Tissue is generally preferred for initial genomic profiling because it contains a higher concentration of tumor DNA, allowing for more accurate detection of somatic mutations. This is especially important in early-stage cancers or tumors that do not shed much DNA into the bloodstream to be detectable by liquid biopsy. The tissue also allows for additional analyses like immunohistochemistry for PD-L1 or assessment of tumor histology to guide therapy. Further, immunohistochemistry plays an important role in precision medicine by identifying protein biomarkers to help determine the use of immune checkpoint inhibitors in NSCLC, triple-negative breast cancer, and urothelial carcinoma. Blood-based tests (ie, liquid biopsies) generally yield lower tumor DNA and do not inherently offer deeper sequencing but are generally more cost-effective than tissue biopsies. Regulatory agencies currently accept blood-based tests (eg, FDA-approved liquid biopsies), but they are typically used when tissue is unavailable or there is insufficient tissue. Learn more about tissue-based profiling Liquid biopsy, particularly through the analysis of circulating tumor DNA (ctDNA), has emerged as a valuable tool for monitoring MRD after treatment. By detecting small amounts of tumor-derived genetic material in the blood, liquid biopsy enables early identification of molecular relapse, often before clinical or radiographic evidence of recurrence is apparent. This makes it particularly useful in post-treatment surveillance of cancers such as colorectal, breast, and NSCLC. Diagnosing lymphomas typically requires tissue biopsy to assess architectural patterns and immunophenotyping; it is also commonly regarded as the standard for diagnosis. PD-L1 expression is a protein-based biomarker typically measured by immunohistochemistry on tissue samples, not usually through ctDNA. However, researchers have stated, 'ctDNA response is a potential biomarker for predicting the efficacy and prognosis of first-line PD-1 inhibitor therapy combined with chemotherapy' in patients with advanced gastric cancer. ctDNA also has been shown to predict responses in patients using PD-1/PD-L1 immune checkpoint inhibitors. Tumor staging usually relies on imaging modalities and pathologic evaluation rather than ctDNA analysis alone. Learn more about clinical practice guidelines in the use of precision medicine in oncology. A high TMB is considered useful because it is associated with abnormal proteins that make the tumor more recognizable to the immune system. TMB is measured using NGS by counting the number of somatic, nonsynonymous mutations per megabase of DNA; it is typically assessed using WES or large targeted panels. A TMB of 10 or more mutations per megabase is considered 'high,' based on data from the KEYNOTE-158 trial. This led to the FDA approval of an immune checkpoint inhibitor for TMB-high solid tumors, for example. High TMB is not usually linked to fewer side effects; side effect profiles tend to depend on the therapy, not mutation count. Low TMB has been shown to lead to fewer neoantigens and typically less immune visibility. Typically, TMB directly measures the number of mutations, not PD-L1 protein expression. Learn more about immunotherapy diagnostics.

Time Business News

2 days ago

• Time Business News

Exonerated but Still Wanted: Red Notices That Outlive Legal Cases

VANCOUVER – You win your case. The charges are dropped. A judge clears your name. But months—or even years—later, you find yourself arrested at a border, denied a visa, or blocked by a bank. Why? Because a Red Notice issued by INTERPOL continues to circulate globally, even after the legal grounds for it no longer exist. In a justice system increasingly dependent on digital alerts and automated databases, exoneration doesn't always mean freedom. Amicus International Consulting investigates how outdated or unresolved INTERPOL Red Notices continue to punish the legally innocent, raising urgent questions about due process, data synchronization, and international cooperation. When Innocence Isn't Enough A Red Notice, once issued, can outlive the legal case it was based on. Although it is meant to be temporary—pending extradition or resolution—INTERPOL notices are often not automatically removed even when: Charges are dropped A court rules in favour of the accused A statute of limitations expires A conviction is overturned on appeal This creates a legal phantom: a person who is no longer wanted by law, but still flagged globally as a fugitive. Case Study 1: British Banker Cleared, But Detained in Dubai In 2022, a British national previously accused of fraud in Southeast Asia was acquitted after evidence emerged that a business rival had fabricated the case. Despite the dismissal, he was arrested at Dubai International Airport during a layover, due to a Red Notice that had never been withdrawn. Although the arresting country had no jurisdiction and the extradition request was void, he was held for four days, missed a major business summit, and suffered reputational damage when local media reported on the story. His legal team, working with Amicus, later succeeded in having the Red Notice deleted by the Commission for the Control of INTERPOL Files (CCF). Still, the incident cost him professional contracts and exposed systemic failures in Red Notice management. Why Red Notices Outlast Legal Proceedings There are several reasons why Red Notices persist even after exoneration: Member States Must Notify INTERPOL INTERPOL does not actively monitor ongoing court cases. It relies on the issuing country to voluntarily request removal. Some countries delay or intentionally fail to update INTERPOL on dropped charges. INTERPOL's Bureaucratic Lag Even when removal is requested, data purging can take months . . The General Secretariat in Lyon handles the process and requires a formal internal review. Data Duplication in Third-Party Systems Many private firms (banks, airlines, visa services) mirror INTERPOL databases . . These may not update in real time—or at all—even when a Red Notice is deleted. Legal Limbo: The Digital Consequences Even after being cleared in court, an individual listed in INTERPOL's system may: Be detained at international borders Lose banking relationships due to KYC/AML compliance Have visa applications rejected or delayed Be barred from working in regulated industries Suffer reputational loss, especially if their Red Notice was publicly visible The human and economic cost of this 'residual criminality' can be devastating. Case Study 2: Journalist Exonerated, Still Flagged in Europe In 2021, a Middle Eastern journalist exiled in Europe won asylum and later had criminal defamation charges against her dismissed by the Supreme Court of her home country. Yet a Red Notice remained active, and she was detained during travel to Switzerland for a media conference. Authorities initially resisted her release, citing INTERPOL's alert. Only after Amicus submitted a dossier with court records and asylum documentation was she allowed to continue her journey. It took another seven months for the CCF to delete the outdated notice. Who Is Responsible for Removal? The responsibility to remove a Red Notice lies with: The Issuing Country : They must notify INTERPOL of legal developments. : They must notify INTERPOL of legal developments. The INTERPOL General Secretariat : Must process removals efficiently. : Must process removals efficiently. The CCF May act independently if a formal complaint is filed. May act independently if a formal complaint is filed. The Subject or their legal team must often initiate contact to push for deletion. This fragmented process creates a bottleneck, especially when legal representation is absent or under-resourced. The CCF: The Last Hope for the Wrongfully Listed The Commission for the Control of INTERPOL's Files (CCF) is the only body authorized to review and delete Red Notices. Its process is confidential, written, and can take 6–12 months. Grounds for deletion include: Case dismissal or acquittal Violation of due process in the origin country Political or discriminatory motive Expiry of the statute of limitations Contradiction with asylum or refugee status While the CCF plays a vital role, its slow pace and limited enforcement power often mean that individuals remain trapped in legal uncertainty. Case Study 3: Businesswoman Exonerated in U.S., Flagged Abroad A dual citizen of the U.S. and West Africa was exonerated in a high-profile corporate embezzlement case in 2020. A federal court found the charges unfounded and politically retaliatory. However, INTERPOL had already issued a Red Notice. Although the U.S. courts cleared her, she was denied entry to Canada, where the Red Notice still appeared in immigration systems. It took Amicus and a Canadian legal team three months to coordinate with authorities and have her travel clearance reinstated. The Red Notice was eventually deleted, but her ability to operate in global finance remained impaired. Amicus Intervention: Legal Strategy Against Old Alerts Amicus International Consulting works with clients whose legal cases are resolved but whose Red Notices remain active. Our services include: Petitioning the CCF for deletion Requesting post-resolution updates from issuing countries Coordinating with immigration and banking compliance units Advising on travel and visa risks during review periods Reputation and media management for high-profile individuals 'Red Notices don't die just because the case does,' said a legal advisor at Amicus. 'You need to bury them legally—or they'll bury your freedom.' Private Sector Fallout: When Banks, Airlines, and Visa Services Don't Get the Memo Even after a Red Notice is deleted, the ripple effects continue: Banks may keep compliance flags for years , fearing future liability. , fearing future liability. Airlines may block bookings from blocked names via API-PNR systems. from blocked names via API-PNR systems. Visa systems, such as ESTA, ETIAS, and eTA, may automatically reject applicants with past INTERPOL flags. may automatically reject applicants with past INTERPOL flags. Background check companies may cite old or archived Red Notices. Amicus offers digital hygiene audits and private-sector erasure campaigns to mitigate ongoing risk. Case Study 4: Interpol Notice Deleted, But Identity Still Tainted In 2023, Amicus represented a Balkan IT executive who had a Red Notice removed after being cleared of charges in Croatia. Yet, his LinkedIn, banking apps, and even air ticketing profiles continued to reject verification due to cached data from third-party vendors. A year-long campaign of legal requests and GDPR filings finally removed the last traces of the outdated notice, but not before he lost clients and had to close his consultancy firm. Policy Recommendations: Preventing Post-Exoneration Injustice To prevent future harm, Amicus and human rights partners advocate for: Automatic removal protocols triggered by issuing countries upon exoneration triggered by issuing countries upon exoneration Real-time data syncing between INTERPOL and third-party users between INTERPOL and third-party users Mandatory Red Notice expiration after legal closure, unless extended by judicial order Red Notice review board with faster appeal windows for cleared individuals Global standard for data privacy and reputation restoration Until then, legal vigilance remains the only defence against a system that exceeds its mandate. Case Study 5: Politician Cleared, Still Blocked from Travel A former Central Asian diplomat, acquitted of corruption charges by an international court in 2021, continued to face travel restrictions in the EU and Asia-Pacific because his Red Notice had not been removed. Despite repeated requests, the issuing country refused to notify INTERPOL. Amicus filed an independent appeal with the CCF, resulting in the deletion nearly a year later. The gap between legal reality and INTERPOL's records had cost him three years of international engagement and stalled the humanitarian work he led. 📞 Contact Information Phone: +1 (604) 200-5402 Email: info@ Website: Follow Us: 🔗 LinkedIn 🔗 Twitter/X 🔗 Facebook 🔗 Instagram TIME BUSINESS NEWS